Charu Aggarwal, MD, MPH

Non-small cell lung cancer mortality decreased substantially among the general U.S. population between 2013 and 2016, according to results of a retrospective study published in The New England Journal of Medicine.

Prior use of chemotherapy appeared associated with an increased risk for death among patients with lung or other thoracic cancers and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

BARCELONA — AMG 510 appeared well-tolerated and showed promising antitumor activity among patients with locally advanced or metastatic non-small cell lung cancer, with 96% of patients achieving disease control, according to phase 1 study results presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The availability and approval of checkpoint inhibitors has transformed the management of metastatic head and neck squamous cell carcinoma.

ATLANTA — Osimertinib plus intermittent selumetinib demonstrated preliminary antitumor activity and acceptable toxicity in patients with EGFR-mutated non-small cell lung cancer whose disease progressed during prior treatment with an EGFR tyrosine kinase inhibitor, according to results of the phase 1b TATTON study presented at American Association for Cancer Research Annual Meeting.

CHICAGO — An ultra-deep sequencing technique detected circulating tumor DNA in plasma at high rates of concordance with tumor tissue among patients with breast, lung and prostate cancers, according to study results presented at the ASCO Annual Meeting.